GHRH (1–44) vs Hexarelin
Both GHRH (1–44) and Hexarelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
GHRH (1–44)
Evidence AGrowth Hormone Releasing Hormone, full sequence
The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.
View full GHRH (1–44) profile →Hexarelin
Evidence BHexarelin (HEX)
The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.
View full Hexarelin profile →Side-by-Side
| Attribute | GHRH (1–44) | Hexarelin |
|---|---|---|
| Evidence Grade | A | B |
| FDA Status | FDA-approved (Geref) historically as diagnostic GH stimulant; current US availability limited | Not FDA-approved — research compound (cardioprotective signals investigated) |
| Typical Dose | 1 mcg/kg IV (diagnostic test) | 100 mcg, 1–2 times daily (subcutaneous) |
| Clinics Indexed | 22 | 41 |
| Categories | growth-hormone | growth-hormone, recovery |
Key reported benefits — GHRH (1–44)
- ✓Endogenous GH stimulation
- ✓Diagnostic GH testing
Key reported benefits — Hexarelin
- ✓Strongest GH spike of GHRPs
- ✓Cardioprotective signals
- ✓Recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.